HUTCHMED (00013) will hold an expert interpretation meeting to discuss the latest clinical data on savolitinib for the treatment of non-small cell lung cancer.

Zhitong Finance APP News, HUTCHMED (00013) announces that it will jointly hold an online expert briefing for analysts and investors with Citigroup Global Markets Asia Limited (referred to as Citi) to discuss the latest Phase III clinical data on savolitinib for the treatment of MET-driven non-small cell lung cancer recently announced at the 2026 European Society for Medical Oncology (ESMO) Annual Congress. The online meeting will be held on November 5, 2026 (Thursday) at 4:30 p.m. Hong Kong Time / 8:30 a.m. Greenwich Mean Time / 3:30 a.m. Eastern Time.